This is a single-centre retrospective analysis of real-life patient management. While the study population is limited to SSc-PAH, there is no control population. Treatment strategies have evolved over time, with treprostinil being the prostanoid of choice in the early years of the registry and epoprostenol more recently. In line with UK commissioning policy, patients have their endothelin receptor antagonist therapy withdrawn after intiating prostanoid therapy, thus UK practice may not reflect other developed countries.
Rheumatology. 2022;61(3):1106-1114. © 2022 Oxford University Press